Cancer: antitumor effects of octreotide LAR, a somatostatin analog
- PMID: 20336162
- DOI: 10.1038/nrendo.2010.3
Cancer: antitumor effects of octreotide LAR, a somatostatin analog
Abstract
Treatment of nonfunctioning neuroendocrine tumors with somatostatin analogs has been controversial, given the low antitumor effects of these drugs. The ProMid study group now reports that octreotide lar (long-acting release) has a substantial antitumor effect, with longer progression-free survival compared with placebo in patients with well-differentiated neuroendocrine tumors and low tumor burden.
Comment on
-
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.J Clin Oncol. 2009 Oct 1;27(28):4656-63. doi: 10.1200/JCO.2009.22.8510. Epub 2009 Aug 24. J Clin Oncol. 2009. PMID: 19704057 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
